4basebio PLC

As of December 31, 2025, 4basebio PLC carries a market capitalization of 9.52B, placing it among publicly traded companies globally. Its enterprise value stands at 9.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

4basebio PLC's next confirmed earnings release is scheduled for June 2, 2027.

As of December 31, 2025, 4basebio PLC has 15.48M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, 4basebio PLC maintains a current ratio of 7.31, meaning it holds 7.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, 4basebio PLC's stock has declined approximately 27.59% over the past 52 weeks. The 50-day moving average sits at 516.67, while the 200-day moving average is 523.87.

As of December 31, 2025, 4basebio PLC holds 1.78B in cash and equivalents against 1.67B in total debt, resulting in a net debt position of -190.20M. Total book value stands at 1.01B, with working capital of 1.78B providing operational flexibility.